<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7190742\results\search\disease\results.xml">
  <result pre="RodgersMary A.mary.rodgers@abbott.com1GomathiSelvamurthi2VallariAna1SaravananShanmugam2LucasGregory M.3MehtaShruti4SolomonSunil S.234ClohertyGavin A.1[1], 0000 0004 0366 7505grid.417574.4Abbott Diagnostics," exact="Infectious" post="Disease Research, [2], 0000 0000 9555 1294grid.433847.fYR Gaitonde Centre"/>
  <result pre="A.mary.rodgers@abbott.com1GomathiSelvamurthi2VallariAna1SaravananShanmugam2LucasGregory M.3MehtaShruti4SolomonSunil S.234ClohertyGavin A.1[1], 0000 0004 0366 7505grid.417574.4Abbott Diagnostics, Infectious" exact="Disease" post="Research, [2], 0000 0000 9555 1294grid.433847.fYR Gaitonde Centre for"/>
  <result pre="not been well-characterized. Through subgenomic sequencing of viruses present in" exact="residual" post="plasma from an HIV/HCV prevalence study conducted amongst PWID"/>
  <result pre="amongst PWID across five cities in India in 2016â€&quot;2017, a" exact="total" post="of Nâ€‰=â€‰498 HCV and Nâ€‰=â€‰755 HIV strains were classified"/>
  <result pre="common. Subject terms Virology Medical research Epidemiology Introduction The global" exact="hepatitis C" post="virus (HCV) and human immunodeficiency virus (HIV) pandemics affect"/>
  <result pre="Epidemiology Introduction The global hepatitis C virus (HCV) and human" exact="immunodeficiency" post="virus (HIV) pandemics affect 71 and 36.9 million people,"/>
  <result pre="and 36.9 million people, respectively, who are chronically infected worldwide1,2." exact="Chronic" post="HCV infection damages the liver over the course of"/>
  <result pre="million people, respectively, who are chronically infected worldwide1,2. Chronic HCV" exact="infection" post="damages the liver over the course of decades, putting"/>
  <result pre="of decades, putting HCV patients at higher risk for developing" exact="cirrhosis" post="and hepatocellular carcinoma3. The clinical consequences of HCV infection"/>
  <result pre="developing cirrhosis and hepatocellular carcinoma3. The clinical consequences of HCV" exact="infection" post="are mitigated by treatment with direct acting antivirals (DAAs),"/>
  <result pre="HIV achieved by antiretroviral therapy (ART) reduces the impact of" exact="HIV infection" post="on CD4 T cell counts and improves life expectancy2."/>
  <result pre="achieved by antiretroviral therapy (ART) reduces the impact of HIV" exact="infection" post="on CD4 T cell counts and improves life expectancy2."/>
  <result pre="HCV strains is essential for defining the true extent of" exact="viral" post="diversity and to ensure that diagnostic tests, vaccines, and"/>
  <result pre="ensure that diagnostic tests, vaccines, and therapeutics keep pace with" exact="viral" post="evolution. Considerable viral diversity exists in India, where the"/>
  <result pre="tests, vaccines, and therapeutics keep pace with viral evolution. Considerable" exact="viral" post="diversity exists in India, where the newly recognized HCV"/>
  <result pre="studies in India have been small in scale (13â€&quot;130 participants)," exact="limited" post="to a single subgenomic region, and largely focused on"/>
  <result pre="presents the first large scale characterization of HIV and HCV" exact="viral" post="strains circulating amongst PWID in five cities across Northern,"/>
  <result pre="circulating amongst PWID in five cities across Northern, Northeastern, and" exact="Central" post="India. Materials and Methods Study population Blood samples and"/>
  <result pre="Northern, Northeastern, and Central India. Materials and Methods Study population" exact="Blood" post="samples and surveys were collected from PWID (1000/site) recruited"/>
  <result pre="approved by the IRB. A subset of samples with sufficient" exact="viral" post="load (&amp;gt;3.5â€‰log IU/ml) and remaining volume from 5 cities"/>
  <result pre="this analysis: Amritsar and Delhi in North India, Kanpur in" exact="Central" post="India and Imphal and Aizawl in Northeastern India. Samples"/>
  <result pre="all samples testing positive for HIV using the RealTime HIV-1" exact="viral" post="load assay (Abbott Molecular Diagnostics, Des Plaines, IL, USA)."/>
  <result pre="antibodies were tested for HCV RNA using the RealTime HCV" exact="viral" post="load assay (Abbott Molecular Diagnostics, Des Plaines, IL, USA)."/>
  <result pre="1.81 6n 24 4.82 6â€‰v 1 0.20 U 1 0.20" exact="Total" post="498 Figure 1 HCV phylogenetic and recombinant analysis. (a)"/>
  <result pre="reduced to improve visualization while representing the full range of" exact="viral" post="diversity encountered in study specimens. In particular, CRF branches"/>
  <result pre="were selected for further molecular characterization in this study if" exact="viral" post="load was at least 3â€‰log 10 IU/ml (HCV) or"/>
  <result pre="In total, Nâ€‰=â€‰975 leftover plasma specimens with sufficient volume and" exact="viral" post="load for sequencing that were collected from Nâ€‰=â€‰477 HIV"/>
  <result pre="Nâ€‰=â€‰278 dual positive study participants were sequenced to identify the" exact="viral" post="strains present (Supplemental Fig. 1). HIV viral loads for"/>
  <result pre="to identify the viral strains present (Supplemental Fig. 1). HIV" exact="viral" post="loads for these specimens ranged from 3.5 to 6.9"/>
  <result pre="to 6.9 log10 copies/ml (median 4.8 log10 copies/ml) and HCV" exact="viral" post="loads for included specimens ranged from 3.8 to 7.3"/>
  <result pre="3). Although New Delhi and Kanpur are both located in" exact="Central" post="India, the most highly prevalent strains of HCV were"/>
  <result pre="in New Delhi, indicating that city-level differences exist within the" exact="Central" post="region (Fig.Â 3). This is further supported by the"/>
  <result pre="samples), or both regions (Nâ€‰=â€‰652 samples) were sequenced from a" exact="total" post="of Nâ€‰=â€‰755 HIV positive specimens. Altogether, Nâ€‰=â€‰668 env IDR"/>
  <result pre="found in New Delhi (15, 4.7%) (Fig.Â 3). Three CRF01_AE" exact="infections" post="were identified exclusively in Aizawl (0.4%), and New Delhi"/>
  <result pre="and New Delhi was the only site were subtype A" exact="infections" post="were found (Nâ€‰=â€‰3, 0.4%), consistent with unique localized epidemics"/>
  <result pre="subtype A infections were found (Nâ€‰=â€‰3, 0.4%), consistent with unique" exact="localized" post="epidemics (Fig.Â 3). Table 2 Table of HIV classifications"/>
  <result pre="0.40 C 730 96.69 CRF01 3 0.40 URF 19 2.52" exact="Total" post="755 Table 3 HIV recombinants. Specimen Site+ HCV GT"/>
  <result pre="with HIV and HCV provided an opportunity to directly compare" exact="viral" post="diversity for both viruses within the same individuals. The"/>
  <result pre="identical to the overall proportions of each classification in the" exact="complete" post="sample (TableÂ 4), suggesting that infection with one virus"/>
  <result pre="each classification in the complete sample (TableÂ 4), suggesting that" exact="infection" post="with one virus (HIV or HCV) did not influence"/>
  <result pre="one virus (HIV or HCV) did not influence the strain" exact="acquired" post="in a second viral co-infection. Table 4 Co-infection classifications"/>
  <result pre="HCV) did not influence the strain acquired in a second" exact="viral" post="co-infection. Table 4 Co-infection classifications (N). HIV A C"/>
  <result pre="co-infection. Table 4 Co-infection classifications (N). HIV A C URF" exact="Total" post="HCV 1a 88 2 90 1b 8 8 3a"/>
  <result pre="1 4d 2 2 6 1 1 6n 2 2" exact="Total" post="2 270 6 278 All characterized specimens with residual"/>
  <result pre="2 Total 2 270 6 278 All characterized specimens with" exact="residual" post="volume were screened with additional serological assays to evaluate"/>
  <result pre="specimen with sufficient volume detected as reactive (Fig.Â 4). A" exact="total" post="of Nâ€‰=â€‰474 remaining HCV specimens were subsequently screened with"/>
  <result pre="HCV antigen assay and the results were compared to HCV" exact="viral" post="load. A total of Nâ€‰=â€‰470 samples were detected as"/>
  <result pre="and the results were compared to HCV viral load. A" exact="total" post="of Nâ€‰=â€‰470 samples were detected as reactive or grayzone-reactive"/>
  <result pre="of these specimens were also present in samples of similar" exact="viral" post="load with detectable HCV antigen. Figure 4 Signal to"/>
  <result pre="mean result for each virus classification is represented by a" exact="horizontal" post="bar and error bars indicate standard deviation from the"/>
  <result pre="(Aizawl, Delhi, and Amritsar) confirms that INSTI resistance was not" exact="localized" post="to a single city. Discussion This is the first"/>
  <result pre="a single city. Discussion This is the first large scale" exact="viral" post="diversity study conducted amongst PWID in India, which generated"/>
  <result pre="diversity study conducted amongst PWID in India, which generated Nâ€‰=â€‰1905" exact="viral" post="sequences from Nâ€‰=â€‰975 PWID participants located in five cities"/>
  <result pre="(WHO)47. As part of this goal, 90% of all HCV" exact="infections" post="should be diagnosed by 2030, with 80% of eligible"/>
  <result pre="of recombination in a given sample53. Therefore, we propose that" exact="complete" post="genome sequencing should be conducted to identify the true"/>
  <result pre="sequencing should be conducted to identify the true prevalence of" exact="viral" post="recombinants in India. Since recombination requires co-infection with multiple"/>
  <result pre="and HCV strains identified herein confirmed that higher levels of" exact="viral" post="diversity were present in cities near borders with neighboring"/>
  <result pre="cities (7â€&quot;8 total) than were found in either of the" exact="Central" post="cities of Kanpur (5) or New Delhi (4) (Fig.Â"/>
  <result pre="Asia57. An important purpose of this study was to characterize" exact="viral" post="diversity in India towards the ultimate goal of using"/>
  <result pre="diversity in India towards the ultimate goal of using diverse" exact="viral" post="strains in circulation as a challenge for diagnostic tests."/>
  <result pre="By pairing HIV and HCV sequence data with serological and" exact="viral" post="load data, this surveillance study demonstrated that the ARCHITECT"/>
  <result pre="the importance of continued vigilance against the threats posed by" exact="viral" post="evolution to the accuracy of diagnostic tests. Given that"/>
  <result pre="in treatment and prevention efforts, a sustained effort to track" exact="viral" post="diversity remains a critical component of global strategies to"/>
  <result pre="S.M., and S.S.S. declare no competing interests. References References 1.Global" exact="hepatitis" post="report, 2017. (World Health Organization). 2.World Health Organization, HIV"/>
  <result pre="Organization, HIV Factsheet. (2018). 3.ThriftAPEl-SeragHBKanwalFGlobal epidemiology and burden of HCV" exact="infection" post="and HCV-related diseaseNat Rev Gastroenterol Hepatol20171412213210.1038/nrgastro.2016.17627924080 4.Organization, W. H."/>
  <result pre="Hepatol20171412213210.1038/nrgastro.2016.17627924080 4.Organization, W. H. Close to 3 million people access" exact="hepatitis C" post="cure. (2017). 5.Fauci, A. S., Redfield, R. R., Sigounas,"/>
  <result pre="1990-2015: a systematic review, global survey, and trend analysisThe Lancet." exact="Infectious" post="diseases20191914315510.1016/S1473-3099(18)30647-930509777 7.Gonzalez-CandelasFLopez-LabradorFXBrachoMARecombination in hepatitis C virusViruses201132006202410.3390/v310200622069526 8.RaghwaniJet al.Origin and"/>
  <result pre="global survey, and trend analysisThe Lancet. Infectious diseases20191914315510.1016/S1473-3099(18)30647-930509777 7.Gonzalez-CandelasFLopez-LabradorFXBrachoMARecombination in" exact="hepatitis C" post="virusViruses201132006202410.3390/v310200622069526 8.RaghwaniJet al.Origin and evolution of the unique hepatitis"/>
  <result pre="hepatitis C virusViruses201132006202410.3390/v310200622069526 8.RaghwaniJet al.Origin and evolution of the unique" exact="hepatitis C" post="virus circulating recombinant form 2k/1bJournal of virology2012862212222010.1128/JVI.06184-1122114341 9.KalininaONorderHMukomolovSMagniusLOA natural"/>
  <result pre="recombinant form 2k/1bJournal of virology2012862212222010.1128/JVI.06184-1122114341 9.KalininaONorderHMukomolovSMagniusLOA natural intergenotypic recombinant of" exact="hepatitis C" post="virus identified in St. PetersburgJournal of virology2002764034404310.1128/jvi.76.8.4034-4043.200211907242 10.Torres-CornejoALauerGMHurdles to"/>
  <result pre="Pathogen Resource (ViPR)Methods Mol Biol20191911476910.1007/978-1-4939-8976-8_330593617 12.BorgiaSMet al.Identification of a Novel" exact="Hepatitis" post="C Virus Genotype From Punjab, India: Expanding Classification of"/>
  <result pre="Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of" exact="Hepatitis" post="C Virus Into 8 GenotypesThe Journal of infectious diseases20182181722172910.1093/infdis/jiy40129982508"/>
  <result pre="Classification of Hepatitis C Virus Into 8 GenotypesThe Journal of" exact="infectious" post="diseases20182181722172910.1093/infdis/jiy40129982508 13.HedskogCet al.Identification of 19 Novel Hepatitis C Virus"/>
  <result pre="GenotypesThe Journal of infectious diseases20182181722172910.1093/infdis/jiy40129982508 13.HedskogCet al.Identification of 19 Novel" exact="Hepatitis" post="C Virus Subtypes-Further Expanding HCV ClassificationOpen Forum Infect Dis20196ofz07610.1093/ofid/ofz07630949527"/>
  <result pre="Expanding HCV ClassificationOpen Forum Infect Dis20196ofz07610.1093/ofid/ofz07630949527 14.SmithDBet al.Expanded classification of" exact="hepatitis C" post="virus into 7 genotypes and 67 subtypes: updated criteria"/>
  <result pre="subtypes: updated criteria and genotype assignment web resourceHepatology20145931832710.1002/hep.2674424115039 15.AmjeshRNairASSugunanVSDiversity of" exact="Hepatitis" post="C virus in Southern India Based on 5â€™UTR SequenceIndian"/>
  <result pre="SequenceIndian J Virol20122334935310.1007/s13337-012-0103-224293823 16.BarmanBBoraKLynrahKGLyngdohWVJamilMHepatitis C virus and its genotypes in" exact="chronic" post="liver disease patients from Meghalaya, Northeast IndiaIndian J Med"/>
  <result pre="J Virol20122334935310.1007/s13337-012-0103-224293823 16.BarmanBBoraKLynrahKGLyngdohWVJamilMHepatitis C virus and its genotypes in chronic" exact="liver disease" post="patients from Meghalaya, Northeast IndiaIndian J Med Microbiol20183637638010.4103/ijmm.IJMM_17_37130429390 17.PrakashSShuklaSRamakrishnaVJainADistribution"/>
  <result pre="Virol20122334935310.1007/s13337-012-0103-224293823 16.BarmanBBoraKLynrahKGLyngdohWVJamilMHepatitis C virus and its genotypes in chronic liver" exact="disease" post="patients from Meghalaya, Northeast IndiaIndian J Med Microbiol20183637638010.4103/ijmm.IJMM_17_37130429390 17.PrakashSShuklaSRamakrishnaVJainADistribution"/>
  <result pre="patients from Meghalaya, Northeast IndiaIndian J Med Microbiol20183637638010.4103/ijmm.IJMM_17_37130429390 17.PrakashSShuklaSRamakrishnaVJainADistribution of" exact="hepatitis C" post="genotypes in Uttar Pradesh, India; rare genotype 4 detectedJournal"/>
  <result pre="detectedJournal of medical virology2018901875188110.1002/jmv.2527730085356 18.PanyalaBRet al.Genotype distribution in relation to" exact="viral" post="load in a large cohort of Indian patients with"/>
  <result pre="viral load in a large cohort of Indian patients with" exact="chronic hepatitis C" post="virus infection: A retrospective analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet al.The"/>
  <result pre="load in a large cohort of Indian patients with chronic" exact="hepatitis C" post="virus infection: A retrospective analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet al.The"/>
  <result pre="infection: A retrospective analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet al.The burden of" exact="hepatitis C" post="virus infection in Punjab, India: A population-based serosurveyPloS one201813e020046110.1371/journal.pone.020046130048454"/>
  <result pre="retrospective analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet al.The burden of hepatitis C" exact="virus infection" post="in Punjab, India: A population-based serosurveyPloS one201813e020046110.1371/journal.pone.020046130048454 20.GuptaDet al.Recombination"/>
  <result pre="analysisIndian J Gastroenterol20193811011610.1007/s12664-019-00934-x30903612 19.SoodAet al.The burden of hepatitis C virus" exact="infection" post="in Punjab, India: A population-based serosurveyPloS one201813e020046110.1371/journal.pone.020046130048454 20.GuptaDet al.Recombination"/>
  <result pre="in Punjab, India: A population-based serosurveyPloS one201813e020046110.1371/journal.pone.020046130048454 20.GuptaDet al.Recombination in" exact="hepatitis C" post="virus is not uncommon among people who inject drugs"/>
  <result pre="and evolution: journal of molecular epidemiology and evolutionary genetics in" exact="infectious" post="diseases20174815616310.1016/j.meegid.2016.12.00127923769 21.SenguptaSet al.Polymorphism of HIV-1 gag (p17) gene from"/>
  <result pre="infectious diseases20174815616310.1016/j.meegid.2016.12.00127923769 21.SenguptaSet al.Polymorphism of HIV-1 gag (p17) gene from" exact="female" post="sex workers in Calcutta, IndiaArchives of virology20051502117212410.1007/s00705-005-0562-515959835 22.SahniAKPrasadVVSethPGenomic diversity"/>
  <result pre="workers in Calcutta, IndiaArchives of virology20051502117212410.1007/s00705-005-0562-515959835 22.SahniAKPrasadVVSethPGenomic diversity of human" exact="immunodeficiency" post="virus type-1 in IndiaInt J STD AIDS20021311511810.1258/095646202192474911839166 23.KhanIFVajpayeeMPrasadVVSethPGenetic diversity"/>
  <result pre="type-1 in IndiaInt J STD AIDS20021311511810.1258/095646202192474911839166 23.KhanIFVajpayeeMPrasadVVSethPGenetic diversity of HIV" exact="type 1" post="subtype C env gene sequences from IndiaAIDS research and"/>
  <result pre="characteristics of V3 region and predicted co-receptor usage of human" exact="immunodeficiency" post="viruses infecting north IndiansJ Microbiol20125086987310.1007/s12275-012-2136-z23124759 26.PrakashSSKalraRLodhaRKabraSKLuthraKDiversity of HIV type"/>
  <result pre="human immunodeficiency viruses infecting north IndiansJ Microbiol20125086987310.1007/s12275-012-2136-z23124759 26.PrakashSSKalraRLodhaRKabraSKLuthraKDiversity of HIV" exact="type 1" post="envelope (V3-V5) sequence in HIV type 1-infected Indian childrenAIDS"/>
  <result pre="1-infected Indian childrenAIDS research and human retroviruses20122850550910.1089/AID.2011.020621902590 27.NeogiUSharmaYSoodVWanchuABanerjeaACDiversity of HIV" exact="type 1" post="long terminal repeat (LTR) sequences following mother-to-child transmission in"/>
  <result pre="of unique recombinant formsJournal of medical virology20178998999910.1002/jmv.2473827869320 30.SolomonSSet al.Burden of" exact="hepatitis C" post="virus disease and access to hepatitis C virus services"/>
  <result pre="formsJournal of medical virology20178998999910.1002/jmv.2473827869320 30.SolomonSSet al.Burden of hepatitis C virus" exact="disease" post="and access to hepatitis C virus services in people"/>
  <result pre="30.SolomonSSet al.Burden of hepatitis C virus disease and access to" exact="hepatitis C" post="virus services in people who inject drugs in India:"/>
  <result pre="people who inject drugs in India: a cross-sectional studyThe Lancet." exact="Infectious" post="diseases201515364510.1016/S1473-3099(14)71045-X25486851 31.SolomonSSet al.Respondent-driven sampling for identification of HIV- and"/>
  <result pre="of human pegivirus 2 in a large Cameroonian cohortJournal of" exact="viral" post="hepatitis201926303710.1111/jvh.1299630187640 35.HallTBioEdit: a user-friendly biological sequence alignment editor and"/>
  <result pre="and quantification in the diagnosis and management of patients with" exact="chronic hepatitis C" post="receiving an all-oral, interferon-free regimen. Antiviral therapy, 10.3851/IMP3042 (2016)."/>
  <result pre="quantification in the diagnosis and management of patients with chronic" exact="hepatitis C" post="receiving an all-oral, interferon-free regimen. Antiviral therapy, 10.3851/IMP3042 (2016)."/>
  <result pre="genotype 1 infected patientsJournal of virological methods2017245141810.1016/j.jviromet.2017.03.00228359920 38.ChevaliezSSoulierAPoiteauLBouvier-AliasMPawlotskyJMClinical utility of" exact="hepatitis C" post="virus core antigen quantification in patients with chronic hepatitis"/>
  <result pre="of hepatitis C virus core antigen quantification in patients with" exact="chronic hepatitis" post="CJournal of clinical virology: the official publication of the"/>
  <result pre="hepatitis C virus core antigen quantification in patients with chronic" exact="hepatitis" post="CJournal of clinical virology: the official publication of the"/>
  <result pre="CJournal of clinical virology: the official publication of the Pan" exact="American" post="Society for Clinical Virology20146114514810.1016/j.jcv.2014.05.01424973282 39.LamouryFMJet al.Evaluation of a Hepatitis"/>
  <result pre="Pan American Society for Clinical Virology20146114514810.1016/j.jcv.2014.05.01424973282 39.LamouryFMJet al.Evaluation of a" exact="Hepatitis" post="C Virus Core Antigen Assay in Plasma and Dried"/>
  <result pre="Hepatitis C Virus Core Antigen Assay in Plasma and Dried" exact="Blood" post="Spot SamplesJ Mol Diagn20182062162710.1016/j.jmoldx.2018.05.01029959023 40.MediciMCet al.Evolving strategy for HCV"/>
  <result pre="hospitalJournal of clinical virology: the official publication of the Pan" exact="American" post="Society for Clinical Virology201677929810.1016/j.jcv.2016.02.01726921741 41.MohamedZet al.Clinical utility of HCV"/>
  <result pre="persons with substance use disordersJ Subst Abuse Treat201778374210.1016/j.jsat.2017.04.01128554601 43.RheeSYet al.Human" exact="immunodeficiency" post="virus reverse transcriptase and protease sequence databaseNucleic acids research20033129830310.1093/nar/gkg10012520007"/>
  <result pre="2017 report. Annual Report NACO 2016-2017, 339-407 (2017). 46.GoelASeguyNAggarwalRBurden of" exact="hepatitis C" post="virus infection in India: A systematic review and meta-analysisJournal"/>
  <result pre="Annual Report NACO 2016-2017, 339-407 (2017). 46.GoelASeguyNAggarwalRBurden of hepatitis C" exact="virus infection" post="in India: A systematic review and meta-analysisJournal of gastroenterology"/>
  <result pre="Report NACO 2016-2017, 339-407 (2017). 46.GoelASeguyNAggarwalRBurden of hepatitis C virus" exact="infection" post="in India: A systematic review and meta-analysisJournal of gastroenterology"/>
  <result pre="and meta-analysisJournal of gastroenterology and hepatology20193432132910.1111/jgh.1446630176181 47.Organization, W. H. Combating" exact="hepatitis" post="B and C to reach elimination by 2030. Advocacy"/>
  <result pre="(kPCR)Journal of clinical virology: the official publication of the Pan" exact="American" post="Society for Clinical Virology20135852252710.1016/j.jcv.2013.09.00524095028 49.LaRueHRigaliLBalada-LlasatJMPancholiPPerformance of the Abbott RealTime"/>
  <result pre="Virology20135852252710.1016/j.jcv.2013.09.00524095028 49.LaRueHRigaliLBalada-LlasatJMPancholiPPerformance of the Abbott RealTime and Roche Cobas TaqMan" exact="hepatitis C" post="virus (HCV) assays for quantification of HCV genotypesJournal of"/>
  <result pre="of HCV genotypesJournal of clinical microbiology2012501769177210.1128/JCM.06723-1122378914 50.HezodeCPan-genotypic treatment regimens for" exact="hepatitis C" post="virus: Advantages and disadvantages in high- and low-income regionsJournal"/>
  <result pre="virus: Advantages and disadvantages in high- and low-income regionsJournal of" exact="viral" post="hepatitis2017249210110.1111/jvh.1263527862695 51.ZorattiMJet al.Pangenotypic direct acting antivirals for the treatment"/>
  <result pre="hepatitis2017249210110.1111/jvh.1263527862695 51.ZorattiMJet al.Pangenotypic direct acting antivirals for the treatment of" exact="chronic hepatitis C" post="virus infection: A systematic literature review and meta-analysisEClinicalMedicine20201810023710.1016/j.eclinm.2019.12.00731922124 52.Soria,"/>
  <result pre="51.ZorattiMJet al.Pangenotypic direct acting antivirals for the treatment of chronic" exact="hepatitis C" post="virus infection: A systematic literature review and meta-analysisEClinicalMedicine20201810023710.1016/j.eclinm.2019.12.00731922124 52.Soria,"/>
  <result pre="A. et al. Comparison of three therapeutic regimens for genotype-3" exact="hepatitis C" post="virus infection in a large real-life multicenter cohort. Liver"/>
  <result pre="al. Comparison of three therapeutic regimens for genotype-3 hepatitis C" exact="virus infection" post="in a large real-life multicenter cohort. Liver Int, 10.1111/liv.14386"/>
  <result pre="Comparison of three therapeutic regimens for genotype-3 hepatitis C virus" exact="infection" post="in a large real-life multicenter cohort. Liver Int, 10.1111/liv.14386"/>
  <result pre="D. a. World Drug Report. (2019). 55.SahaKet al.Transmission dynamics of" exact="hepatitis C" post="virus among intra venous drug users in the border"/>
  <result pre="and evolution: journal of molecular epidemiology and evolutionary genetics in" exact="infectious" post="diseases201424576710.1016/j.meegid.2014.03.00824650917 56.KhanSZahidMQureshiMAMughalMNUjjanIDHIV-1 genetic diversity, geographical linkages and antiretroviral drug"/>
  <result pre="individuals from PakistanArchives of virology2018163334010.1007/s00705-017-3564-128942522 57.SievertWet al.A systematic review of" exact="hepatitis C" post="virus epidemiology in Asia, Australia and EgyptLiver Int201131Suppl 2618010.1111/j.1478-3231.2011.02540.x21651703"/>
 </snippets>
</snippetsTree>
